Advanced Enzyme Technologies Ltd · NSE:ADVENZYMES
Advanced Enzyme Technologies — Q1 FY2020 Earnings Presentation
14 slides from Advanced Enzyme Technologies's earnings presentation, Aug 10, 2019
Slide 1: Earnings Presentation Q1FY20
Earnings Presentation Q1FY20
Slide 2: Disclaimer
Disclaimer This information may contain certain forward-looking statements/details in the current scenario, which is extremely dynamic and increasingly fraught with risks and uncertainties. Actual results, performances, achievements or sequence of events may be materially different from the views ex
Slide 3: Company Overview: What are enzymes?
Company Overview What are enzymes? Enzymes are natural protein molecules that act as catalysts within living cells, produced by all living organisms. Function as specialized catalysts and accelerate the pace of biochemical reactions. Advanced uses enzymes to replace chemicals in, and improve efficie
Slide 4: Advanced Enzyme Technologies Limited – A Rising Global Star
Advanced Enzyme Technologies Limited – A Rising Global Star Revenue (₹ mn) 1st Indian enzyme company Highest market share in India Listed integrated enzyme player globally 4,196 2nd 2nd Amongst Top 15 Global Enzyme Companies 2,321 Manufacturing Units – 7 R&D Units – 7 FY 15 FY 19 India - 5 USA - 2 I
Slide 5: Results Summary – Q1FY20 (Consolidated)
Results Summary – Q1FY20 (Consolidated) *Revenue (₹ mn) EBITDA (₹ mn) PAT (₹ mn) 1,103 545 1,043 487 312 340 Q1FY19 Q1FY20 Q1FY19 Q1FY20 Q1FY19 Q1FY20 Revenue Breakup ₹ in Million *YoY Growth Animal HC Human HC Industrial Bio-Processing -24% -1% (18%) 0% 7% (47%) Q1FY20 132 807 128 Q1FY19 132 757 12
Slide 6: Revenue Split – Q1FY20
Revenue Split – Q1FY20 Q1FY20 Q1FY19 Segmental Revenue Split (%) Segmental Revenue Split (%) 12% 12% 10% 13% 76% 77% Animal HC Human HC Bio-Processing Animal HC Human HC Bio-Processing Geographical Revenue Split (%) Geographical Revenue Split (%) 2% 2% 6% 4% 45% 51% 41% 44% 3% 2% Asia (ex- India) Ot
Slide 7: Profit & Loss (Consolidated) – Q1FY20
Profit & Loss (Consolidated) – Q1FY20 ₹ in Million except per share data Q1FY20 Q4FY19 Q1FY19 FY19 FY18 Particulars Y-o-Y (%) Y-o-Y (%) Unaudited Audited Unaudited Audited Audited Income from Operations 1,103 1,104 1,043 6% 4,196 3,957 6% Expenses 631 660 611 3% 2,588 2,500 4% Profit from Operations
Slide 8: Results Summary – FY19
Results Summary – FY19 *Revenue (₹ mn) EBITDA (₹ mn) PAT (₹ mn) 4,196 1,159 1,819 3,957 1,640 936 FY18 FY19 FY18 FY19 FY18 FY19 Revenue Breakup ₹ in Million *YoY Growth Animal HC Human HC Industrial Processing -24% (1%) (1%) 10% 9% FY19 493 3,133 482 FY18 498 2,860 444 Note: 1.. On Consolidated Basi
Slide 9: Revenue Split – FY18 vs FY19
Revenue Split – FY18 vs FY19 FY19 FY18 Segmental Revenue Split (%) Segmental Revenue Split (%) 12% 12% 12% 13% 76% 75% Animal HC Human HC Bio-Processing Animal HC Human HC Bio-Processing Geographical Revenue Split (%) Geographical Revenue Split (%) 2% 1% 4% 4% 47% 50% 41% 45% 3% 3% Asia (ex- India)
Slide 10: Balance Sheet (Consolidated) – FY19
Balance Sheet (Consolidated) – FY19 ₹ in Million FY19 FY18 Particulars Audited Audited Assets Property, plant and equipment 1,618 1,667 Capital work-in-progress 105 105 Intangible assets 622 662 Goodwill 2,715 2,584 Other non-current assets 183 143 Current assets 2,821 2,107 Assets held for sale 48
Slide 11: Strong Financial Performance – FY19
Strong Financial Performance – FY19 ₹ in Million Revenue from Operations 2,500 EBIDTA & EBIDTA Margin (%) 50% 47% 45% 4,196 48% 3,957 2,000 45% 42% 3,431 46% 1,870 2,938 1,500 42% 1,654 44% 1,534 2,321 1,000 1,389 42% 931 40% 500 38% 0 36% FY 15 FY 16 FY 17 FY 18 FY 19 FY 15 FY 16 FY 17 FY 18 FY19 E
Slide 12: Strong Financial Performance – FY19
Strong Financial Performance – FY19 Net Working Capital (Days) Net Worth (₹ mn) 128 6,788 119 5,591 4,640 112 110 108 2,781 2,120 FY 15 FY 16 FY 17 FY 18 FY 19 FY 15 FY 16 FY 17 FY 18 FY 19 ROE (%) & ROCE (%) Net Debt to Equity (x) 34% 0.5 26% 27% 27% 26% 0.4 28% 24% 19% 18% 19% 0.1 0.01 0.02 FY 15
Slide 13: Shareholder Information
Shareholder Information Stock Data (As on 08th August 2019) Top 5 Institutional Holders (As on 02nd August 2019) Institutions OS (%) Market Capitalization (₹) 17,666 mn ORBIMED ASIA III MAURITIUS 12.09 HDFC SMALL CAP FUND 3.89 Shares Outstanding 111.6 mn HDFC TRUSTEE COMPANY LTD. A/C HDFC 2.32 Free
Slide 14: Thank You
Thank You Advanced Enzymes 5th Floor, 'A' wing, Sun Magnetica LIC Service Road, Louiswadi Thane (W) 400 604, India Tel: +91-22-4170 3200 Fax: + 91-22-25835159
Advanced Enzyme Technologies — Q1 FY2020 Earnings Presentation on 6ix